Key result
Overexpression of PKC-ε protected the heart against doxorubicin-induced cell apoptosis and oxidative stress by activating SIRT1.
Why the study?
It was unclear whether reduced cardiac PKC-ε expression plays a causal role in doxorubicin-induced cardiotoxicity and through what underlying mechanism PKC-ε may protect against it.
Does PKC-epsilon overexpression prevent doxorubicin-induced cardiotoxicity in mice and cardiomyocytes?
Does PKC-epsilon overexpression prevent doxorubicin-induced cardiotoxicity in mice and cardiomyocytes?
PKC-ε overexpression protects against doxorubicin-induced cardiotoxicity by activating SIRT1, highlighting a potential therapeutic target for chemotherapy-induced heart failure.
Answers are grounded in this paper and cite their sources.
PKC-ε overexpression may protect cardiomyocytes from doxorubicin; leaves open translation to clinical chemotherapy-induced heart failure.
Doxorubicin (DOX)-induced cardiotoxicity (DIC) is known to be associated with reduction of cardiac protein kinase C epsilon (PKC-ε). PKC-ε promotes cell survival and protects hearts against various stresses. However, it is unclear whether or not the reduction in cardiac PKC-ε expression plays a causal role in DIC and in particular the potential underlying mechanism whereby PKC-ε may protect against DIC. C57BL/6 mice (8-10-week-old) were either treated with DOX administered intraperitoneally for a duration of 4 weeks to produce cardiotoxicity, or untreated in which mice received the same volume of saline. In vitro, neonatal rat ventricle cardiomyocytes were exposed to DOX for 24 h in the absence or presence of adenovirus overexpressing PKC-ε. Cardiomyocytes in a subgroup were treated with sirtuin-1 (SIRT1) selective inhibitor Ex527. Four weeks after DOX, cardiac contractile function was decreased concomitant with increased serum CK-MB and LDH levels as well as increases in Bax-to-Bcl-2 ratio and Cleaved Caspase 3 proteins expression, while PKC-ε and Sirt1 protein expressions were significantly decreased. In vitro, DOX reduced cardiomyocyte PKC-ε and SIRT1 protein expression, decreased cardiomyocyte viability, and increased LDH release with concomitant increases in oxidative stress and apoptosis. These changes were attenuated by overexpression of PKC-ε. IP study showed that PKC-ε could directly or indirectly bind SIRT1 in cardiomyocytes, and the protect effects of PKC-ε were further canceled by SIRT1 inhibition. In conclusion, activating SIRT1 may represent a major mechanism whereby PKC-ε protects the heart against DOX-induced cell apoptosis and oxidative stress.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied Doxorubicin-induced cardiotoxicity. PKC-ε overexpression vs. Control adenovirus / Saline was evaluated on Cardiomyocyte apoptosis and oxidative stress (p=<0.05). Overexpression of PKC-ε protected the heart against doxorubicin-induced cell apoptosis and oxidative stress by activating SIRT1.
Synapse has enriched 10 related papers. Consider them for comparative context: